GoAI
Get started
Oncolytics Biotech Inc. logo

Oncolytics Biotech Inc.

ONCY

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$0.8431

+$0.0414 · +5.16%

Aug 21, 4:00 PM ET

ONCY company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

25

Expensive

Momentum

38

Weakening

Sentiment

56

Mixed

Risk resilience

35

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of oncology treatments. The company develops pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative advanced and metastatic breast cancer, metastatic pancreatic ductal adenocarcinoma, and anal cancer. It has an agreement with Roche Holding AG to supply its immune checkpoint inhibitors, atezolizumab, for use in its ongoing sponsored studies. Oncolytics Biotech Inc. was incorporated in 1998 and is headquartered in Calgary, Canada.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Jared Kelly
Listed since
Oct 5, 2001
Employees
29

Market position

Day range

Current $0.8431

52-week range

Current $0.8431

Open
$0.80
Previous close
$0.8017
Volume
545.01K
0.43× average
Average volume
1.28M
Average daily volume
Market cap
84.61M USD
Beta
1.14
Market reference 1
50-day average
$0.8542
-1.30% below average
200-day average
$0.9436
-10.65% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-3.38×
P/B (TTM)
-22.58×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
-0.07×
Altman Z-score
-92.9
Piotroski F-score
1 of 9

Financial statements

Income trends

Operating income

−28.73M USD-12.46%

Net income

−28.76M USD-26.17%
Income trends across reported periods−17.25M USD−21.44M USD−25.62M USD−29.81M USDOperating income, FY2021: −26.23M USDOperating income, FY2022: −19.84M USDOperating income, FY2023: −25.47M USDOperating income, FY2024: −25.54M USDOperating income, FY2025: −28.73M USDNet income, FY2021: −26.3M USDNet income, FY2022: −18.3M USDNet income, FY2023: −20.92M USDNet income, FY2024: −22.79M USDNet income, FY2025: −28.76M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −26.23M USD. Operating income FY2022 −19.84M USD. Operating income FY2023 −25.47M USD. Operating income FY2024 −25.54M USD. Operating income FY2025 −28.73M USD. Net income FY2021 −26.3M USD. Net income FY2022 −18.3M USD. Net income FY2023 −20.92M USD. Net income FY2024 −22.79M USD. Net income FY2025 −28.76M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development13.31M USD15.44M USD13.35M USD11.37M USD12.92M USD
Selling, general, and administrative15.41M USD10.1M USD11.82M USD8.18M USD12.86M USD
Operating expenses28.73M USD25.54M USD25.47M USD19.84M USD26.23M USD
Interest income529.64K USD1.2M USD1.33M USD528K USD—
Depreciation and amortization70K USD87K USD303.78K USD288.83K USD452K USD
Operating income−28.73M USD−25.54M USD−25.47M USD−19.84M USD−26.23M USD
Net income−28.76M USD−22.79M USD−20.92M USD−18.3M USD−26.3M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+16.12%
11 comparable reports
Latest EPS result
-0.08
Estimate -0.05 · Miss by 48.70%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.01-0.06-0.11-0.16Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25BeatQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 7, 2025: actual -0.07, estimate -0.08, surprise +12.50%, Beat. Q2 2025, reported May 14, 2025: actual -0.06, estimate -0.09, surprise +33.33%, Beat. Q3 2025, reported Aug 8, 2025: actual -0.05, estimate -0.11, surprise +54.55%, Beat. Q4 2025, reported Nov 12, 2025: actual -0.1, estimate -0.12, surprise +16.67%, Beat. Q1 2026, reported Mar 30, 2026: actual -0.01, estimate -0.06, surprise +83.13%, Beat. Q2 2026, reported May 14, 2026: actual -0.08, estimate -0.05, surprise -60.00%, Miss. Q3 2026, reported Aug 12, 2026: actual -0.08, estimate -0.054, surprise -48.70%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.07, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

4 institutions
Jones TradingdowngradeBuyHold
RBC CapitalmaintainOutperform
Maxim GroupmaintainBuy

ONCY news

globenewswire.com

Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer

FDA written feedback provides alignment on a potential pivotal Part B expansion of the ongoing REO 033 study Proposed pathway offers potential accelerated approval based on objective response rate and progression-free…

Read source
globenewswire.com

Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

Designation supports development in an estimated $1 billion market where there are no FDA-approved therapies for patients whose disease progresses following first-line standard of care therapy Third Fast Track…

Read source
globenewswire.com

Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial

Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential registrational…

Read source
globenewswire.com

Oncolytics Biotech® Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044

Intellectual property update confirms pelareorep's unique manufacturing process and scalability Previously filed method-of-use patent application expected to provide protection into 2046 Additional patent filings planned…

Read source
globenewswire.com

Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer

SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically active immunotherapy…

Read source
globenewswire.com

Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, today announced initial data from a preclinical study…

Read source

ONCY peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding ONCY

Funds reporting this stock among their holdings, ordered by reported position size.

Invesco NASDAQ Future Gen 200 ETF logoInvesco NASDAQ Future Gen 200 ETFQQQS
Market value
86.2K
Weight
0.38%
AUM
22.98M USD
Expense ratio
0.20%
Price / 1D
$45.0826+1.10%

Continue in GoAI

Research ONCY

research.disclaimer